A Real-World Study of the Effectiveness and Safety of Post-Tafasitamab Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SOHO 2026) - Sep 1, 2026 - Abstract #ABCL-484; Location: LEVEL 3, HALL B3; " This retrospective, US and EU physician-abstracted medical chart review study collected data for adults with R/R DLBCL who received tafasitamab (±lenalidomide) and subsequent CAR-T in second-line (2L), 3L, or 4L...CAR-T therapies administered were axicabtagene ciloleucel (65.1%), followed by lisocabtagene maraleucel (21.9%) and tisagenlecleucel (13.0%)... This large, real-world study indicates that prior exposure to tafasitamab does not appear to compromise the effectiveness or safety of subsequent CAR-T therapy in patients with R/R DLBCL. These real-world study findings support the sequencing strategy of tafasitamab followed by CAR-T. Funding: This study was funded by Incyte Corporation."
CAR T-Cell Therapy • Clinical • IO biomarker • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • CD19
|
|
Narendranath Epperla 1; Kim Saverno 2; Irina Pivneva 3; Sakshi Sethi 4; Lucila Sackmann 2; Andrea Zaffalon 2; Julie Wu 2; Mariana Bastos-Oreiro 5
|